Other languages Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
4.42 ^USD	+5.24%		+0.91%	+3.27%

Jul. 10	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184	CI
Jul. 01	Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell Microcap Value Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184	Jul. 10
Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan	Jun. 12
Lantern Pharma Inc. Receives Certificate of Patent from Japanese Patent Office for Composition of Matter Covering Drug Candidate LP-284	Jun. 12
Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...	May. 13
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration	May. 06
Lantern Pharma Inc. Announces A Strategic AI-Driven Collaboration with Oregon Therapeutics to Optimize the Development of its First-In-Class Protein Disulfide Isomerase Inhibitor Drug Candidate XCE853 in Novel and Targeted Cancer Indications	May. 06
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan	Apr. 22
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284	Mar. 15
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR	Mar. 04
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers	Feb. 15
Lantern Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company	23-10-20
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma	23-10-03
Lantern Pharma Doses First Patient in Phase 1 Trial of Advanced Solid Tumor Drug Candidate	23-09-25
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors	23-09-25
Sector Update: Health Care Stocks Mixed Monday Afternoon	23-09-18
FDA Clears Lantern Pharma's Investigation New-Drug Application for LP-284	23-09-18
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin?s Lymphomas	23-09-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Other languages

Filters